AXL and ovarian cancer: Another phase I/II clinical trial (NCT04019288) was designed and was commenced in 2019 to evaluate the safety and clinical benefit of durvalumab plus AVB-S6-500 (an AXL inhibitor) in platinum-resistant ovarian cancer patients.